Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 57209931480
Scopus Author ID: 56323797500

Activities

Collapse all

Employment (1)

Takeda Oncology: Cambridge, MA, US

Employment
Source: Self-asserted source
Neeraj Gupta

Works (50 of 54)

Items per page:
Page 1 of 2

Effect of severe renal impairment on the pharmacokinetics of brigatinib

Investigational New Drugs
2021 | Journal article
DOI: 10.1007/s10637-021-01095-5
EID:

2-s2.0-85103067046

Part of ISSN: 15730646 01676997
Contributors: Gupta, N.; Hanley, M.J.; Kerstein, D.; Tugnait, M.; Narasimhan, N.; Marbury, T.C.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

Clinical Pharmacology in Drug Development
2021 | Journal article
DOI: 10.1002/cpdd.967
EID:

2-s2.0-85108318441

Part of ISSN: 21607648 2160763X
Contributors: Zhang, S.; Jin, S.; Griffin, C.; Feng, Z.; Lin, J.; Venkatakrishnan, K.; Gupta, N.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Clinical Pharmacokinetics
2021 | Journal article
DOI: 10.1007/s40262-020-00929-4
EID:

2-s2.0-85089740041

Part of ISSN: 11791926 03125963
Contributors: Gupta, N.; Wang, X.; Offman, E.; Prohn, M.; Narasimhan, N.; Kerstein, D.; Hanley, M.J.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

Journal of Clinical Pharmacology
2021 | Journal article
DOI: 10.1002/jcph.1974
EID:

2-s2.0-85118148326

Part of ISSN: 15524604 00912700
Contributors: Zhou, X.; Ouerdani, A.; Diderichsen, P.M.; Gupta, N.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

Clinical Pharmacology in Drug Development
2021 | Journal article
DOI: 10.1002/cpdd.951
EID:

2-s2.0-85107629931

Part of ISSN: 21607648 2160763X
Contributors: Zhang, S.; Jin, S.; Griffin, C.; Feng, Z.; Lin, J.; Baratta, M.; Brake, R.; Venkatakrishnan, K.; Gupta, N.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non-Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

CPT: Pharmacometrics and Systems Pharmacology
2020 | Journal article
DOI: 10.1002/psp4.12569
EID:

2-s2.0-85098092577

Part of ISSN: 21638306
Contributors: Gupta, N.; Wang, X.; Offman, E.; Rich, B.; Kerstein, D.; Hanley, M.; Diderichsen, P.M.; Zhang, P.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Journal of Clinical Oncology
2020 | Journal article
DOI: 10.1200/JCO.20.00505
EID:

2-s2.0-85094933151

Part of ISSN: 15277755 0732183X
Contributors: Camidge, D.R.; Kim, H.R.; Ahn, M.-J.; Yang, J.C.H.; Han, J.-Y.; Hochmair, M.J.; Lee, K.H.; Delmonte, A.; García Campelo, M.R.; Kim, D.-W. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC

Journal of Thoracic Oncology
2020 | Journal article
DOI: 10.1016/j.jtho.2020.02.011
EID:

2-s2.0-85082806071

Part of ISSN: 15561380 15560864
Contributors: Ng, T.L.; Narasimhan, N.; Gupta, N.; Venkatakrishnan, K.; Kerstein, D.; Camidge, D.R.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

Clinical Pharmacology in Drug Development
2020 | Journal article
DOI: 10.1002/cpdd.723
EID:

2-s2.0-85068726414

Part of ISSN: 21607648 2160763X
Contributors: Tugnait, M.; Gupta, N.; Hanley, M.J.; Sonnichsen, D.; Kerstein, D.; Dorer, D.J.; Venkatakrishnan, K.; Narasimhan, N.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development

Clinical Pharmacology and Therapeutics
2020 | Journal article
DOI: 10.1002/cpt.1667
EID:

2-s2.0-85075160962

Part of ISSN: 15326535 00099236
Contributors: Gupta, N.; Bottino, D.; Simonsson, U.S.H.; Musante, C.J.; Bueters, T.; Rieger, T.R.; Macha, S.; Chenel, M.; Fancourt, C.; Kanodia, J. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

European Journal of Cancer
2019 | Journal article
DOI: 10.1016/j.ejca.2018.09.011
EID:

2-s2.0-85056777478

Part of ISSN: 18790852 09598049
Contributors: Dimopoulos, M.A.; Grosicki, S.; Jędrzejczak, W.W.; Nahi, H.; Gruber, A.; Hansson, M.; Gupta, N.; Byrne, C.; Labotka, R.; Teng, Z. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical Pharmacokinetics
2019 | Journal article
DOI: 10.1007/s40262-018-0702-1
EID:

2-s2.0-85052141170

Part of ISSN: 11791926 03125963
Contributors: Gupta, N.; Hanley, M.J.; Xia, C.; Labotka, R.; Harvey, R.D.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Clinical Pharmacology and Therapeutics
2019 | Journal article
DOI: 10.1002/cpt.1047
EID:

2-s2.0-85044205029

Part of ISSN: 15326535 00099236
Contributors: Gupta, N.; Hanley, M.J.; Diderichsen, P.M.; Yang, H.; Ke, A.; Teng, Z.; Labotka, R.; Berg, D.; Patel, C.; Liu, G. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

The Lancet
2019 | Journal article
DOI: 10.1016/S0140-6736(18)33003-4
EID:

2-s2.0-85060020572

Part of ISSN: 1474547X 01406736
Contributors: Dimopoulos, M.A.; Gay, F.; Schjesvold, F.; Beksac, M.; Hajek, R.; Weisel, K.C.; Goldschmidt, H.; Maisnar, V.; Moreau, P.; Min, C.K. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

British Journal of Haematology
2019 | Journal article
DOI: 10.1111/bjh.15679
EID:

2-s2.0-85056763282

Part of ISSN: 13652141 00071048
Contributors: Kumar, S.K.; Grzasko, N.; Delimpasi, S.; Jedrzejczak, W.W.; Grosicki, S.; Kyrtsonis, M.-C.; Spencer, A.; Gupta, N.; Teng, Z.; Byrne, C. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

Clinical Pharmacology in Drug Development
2019 | Journal article
DOI: 10.1002/cpdd.641
EID:

2-s2.0-85058853098

Part of ISSN: 21607648 2160763X
Contributors: Tugnait, M.; Gupta, N.; Hanley, M.J.; Venkatakrishnan, K.; Sonnichsen, D.; Kerstein, D.; Dorer, D.J.; Narasimhan, N.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

Journal of Clinical Pharmacology
2018 | Journal article
DOI: 10.1002/jcph.987
EID:

2-s2.0-85038018592

Part of ISSN: 15524604 00912700
Contributors: Hanley, M.J.; Gupta, N.; Venkatakrishnan, K.; Bessudo, A.; Sharma, S.; O'Neil, B.H.; Wang, B.; van de Velde, H.; Nemunaitis, J.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [<sup>14</sup>C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

Investigational New Drugs
2018 | Journal article
DOI: 10.1007/s10637-017-0509-1
EID:

2-s2.0-85029598878

Part of ISSN: 15730646 01676997
Contributors: Gupta, N.; Zhang, S.; Pusalkar, S.; Plesescu, M.; Chowdhury, S.; Hanley, M.J.; Wang, B.; Xia, C.; Zhang, X.; Venkatakrishnan, K. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

Haematologica
2018 | Journal article
DOI: 10.3324/haematol.2017.185991
EID:

2-s2.0-85052862039

Part of ISSN: 15928721 03906078
Contributors: San-Miguel, J.F.; Gutierrez, M.-A.E.; Špicka, I.; Mateos, M.-V.; Song, K.; Craig, M.D.; Bladé, J.; Hájek, R.; Chen, C.; Di Bacco, A. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Biotransformation of [<sup>14</sup>C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces

Cancer Chemotherapy and Pharmacology
2018 | Journal article
DOI: 10.1007/s00280-018-3671-z
EID:

2-s2.0-85052530653

Part of ISSN: 14320843 03445704
Contributors: Pusalkar, S.; Plesescu, M.; Gupta, N.; Hanley, M.; Venkatakrishnan, K.; Wu, J.-T.; Xia, C.; Zhang, X.; Chowdhury, S.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

New England Journal of Medicine
2018 | Journal article
DOI: 10.1056/NEJMoa1810171
EID:

2-s2.0-85054414228

Part of ISSN: 15334406 00284793
Contributors: Camidge, D.R.; Kim, H.R.; Ahn, M.-J.; Yang, J.C.-H.; Han, J.-Y.; Lee, J.-S.; Hochmair, M.J.; Li, J.Y.-C.; Chang, G.-C.; Lee, K.H. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Journal of Clinical Pharmacology
2018 | Journal article
DOI: 10.1002/jcph.988
EID:

2-s2.0-85040232048

Part of ISSN: 15524604 00912700
Contributors: Gupta, N.; Hanley, M.J.; Venkatakrishnan, K.; Bessudo, A.; Rasco, D.W.; Sharma, S.; O'Neil, B.H.; Wang, B.; Liu, G.; Ke, A. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

Clinical Pharmacology and Therapeutics
2018 | Journal article
DOI: 10.1002/cpt.978
EID:

2-s2.0-85041637334

Part of ISSN: 15326535 00099236
Contributors: Nayak, S.; Sander, O.; Al-Huniti, N.; de Alwis, D.; Chain, A.; Chenel, M.; Sunkaraneni, S.; Agrawal, S.; Gupta, N.; Visser, S.A.G.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development

Clinical and Translational Science
2018 | Journal article
DOI: 10.1111/cts.12524
EID:

2-s2.0-85034830196

Part of ISSN: 17528062 17528054
Contributors: Teng, Z.; Gupta, N.; Hua, Z.; Liu, G.; Samnotra, V.; Venkatakrishnan, K.; Labotka, R.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development

Clinical and Translational Science
2018 | Journal article
DOI: 10.1111/cts.12527
EID:

2-s2.0-85044350429

Part of ISSN: 17528062 17528054
Contributors: Faucette, S.; Wagh, S.; Trivedi, A.; Venkatakrishnan, K.; Gupta, N.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

British Journal of Haematology
2018 | Journal article
DOI: 10.1111/bjh.15394
EID:

2-s2.0-85049668245

Part of ISSN: 13652141 00071048
Contributors: Richardson, P.G.; Hofmeister, C.C.; Rosenbaum, C.A.; Htut, M.; Vesole, D.H.; Berdeja, J.G.; Liedtke, M.; Chari, A.; Smith, S.D.; Lebovic, D. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Blood
2017 | Journal article
DOI: 10.1182/blood-2017-03-771220
EID:

2-s2.0-85026898715

Part of ISSN: 15280020 00064971
Contributors: Sanchorawala, V.; Palladini, G.; Kukreti, V.; Zonder, J.A.; Cohen, A.D.; Seldin, D.C.; Dispenzieri, A.; Jaccard, A.; Schönland, S.O.; Berg, D. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Targeted Oncology
2017 | Journal article
DOI: 10.1007/s11523-017-0524-3
EID:

2-s2.0-85027296067

Part of ISSN: 1776260X 17762596
Contributors: Gupta, N.; Yang, H.; Hanley, M.J.; Zhang, S.; Liu, R.; Kumar, S.; Richardson, P.G.; Skacel, T.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

British Journal of Haematology
2017 | Journal article
DOI: 10.1111/bjh.14733
EID:

2-s2.0-85019089968

Part of ISSN: 13652141 00071048
Contributors: Kumar, S.; Moreau, P.; Hari, P.; Mateos, M.-V.; Ludwig, H.; Shustik, C.; Masszi, T.; Spencer, A.; Hájek, R.; Romeril, K. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib

Journal of Blood Medicine
2017 | Journal article
DOI: 10.2147/JBM.S102328
EID:

2-s2.0-85031286640

Part of ISSN: 11792736
Contributors: Richardson, P.G.; Kumar, S.; Laubach, J.P.; Paba-Prada, C.; Gupta, N.; Berg, D.; van de Velde, H.; Moreau, P.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range

Journal of Clinical Pharmacology
2017 | Journal article
DOI: 10.1002/jcph.906
EID:

2-s2.0-85018801422

Part of ISSN: 15524604 00912700
Contributors: Hanley, M.J.; Mould, D.R.; Taylor, T.J.; Gupta, N.; Suryanarayan, K.; Neuwirth, R.; Esseltine, D.-L.; Horton, T.M.; Aplenc, R.; Alonzo, T.A. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

Clinical Pharmacokinetics
2017 | Journal article
DOI: 10.1007/s40262-017-0526-4
EID:

2-s2.0-85015067117

Part of ISSN: 11791926 03125963
Contributors: Gupta, N.; Diderichsen, P.M.; Hanley, M.J.; Berg, D.; van de Velde, H.; Harvey, R.D.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Journal of Hematology and Oncology
2017 | Journal article
DOI: 10.1186/s13045-017-0501-4
EID:

2-s2.0-85021737696

Part of ISSN: 17568722
Contributors: Hou, J.; Jin, J.; Xu, Y.; Wu, D.; Ke, X.; Zhou, D.; Lu, J.; Du, X.; Chen, X.; Li, J. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis

British Journal of Haematology
2016 | Journal article
DOI: 10.1111/bjh.14125
EID:

2-s2.0-84987728106

Part of ISSN: 13652141 00071048
Contributors: Gupta, N.; Hanley, M.J.; Harvey, R.D.; Badros, A.; Lipe, B.; Kukreti, V.; Berdeja, J.; Yang, H.; Hui, A.-M.; Qian, M. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study

Investigational New Drugs
2016 | Journal article
DOI: 10.1007/s10637-016-0346-7
EID:

2-s2.0-84961992332

Part of ISSN: 15730646 01676997
Contributors: Gupta, N.; Labotka, R.; Liu, G.; Hui, A.-M.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

British Journal of Clinical Pharmacology
2016 | Journal article
DOI: 10.1111/bcp.12991
EID:

2-s2.0-84982975927

Part of ISSN: 13652125 03065251
Contributors: Gupta, N.; Hanley, M.J.; Venkatakrishnan, K.; Perez, R.; Norris, R.E.; Nemunaitis, J.; Yang, H.; Qian, M.G.; Falchook, G.; Labotka, R. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

Journal of Clinical Pharmacology
2016 | Journal article
DOI: 10.1002/jcph.719
EID:

2-s2.0-84988428970

Part of ISSN: 15524604 00912700
Contributors: Gupta, N.; Hanley, M.J.; Venkatakrishnan, K.; Wang, B.; Sharma, S.; Bessudo, A.; Hui, A.-M.; Nemunaitis, J.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles

Clinical and Translational Science
2016 | Journal article
DOI: 10.1111/cts.12386
EID:

2-s2.0-84958604594

Part of ISSN: 17528062 17528054
Contributors: Venkatakrishnan, K.; Burgess, C.; Gupta, N.; Suri, A.; Takubo, T.; Zhou, X.; Demuria, D.; Lehnert, M.; Takeyama, K.; Singhvi, S. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

Cancer Chemotherapy and Pharmacology
2015 | Journal article
DOI: 10.1007/s00280-015-2815-7
EID:

2-s2.0-84939476079

Part of ISSN: 14320843 03445704
Contributors: Gupta, N.; Huh, Y.; Hutmacher, M.M.; Ottinger, S.; Hui, A.-M.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Journal of Hematology and Oncology
2015 | Journal article
DOI: 10.1186/s13045-015-0198-1
EID:

2-s2.0-84940658248

Part of ISSN: 17568722
Contributors: Gupta, N.; Goh, Y.T.; Min, C.-K.; Lee, J.H.; Kim, K.; Wong, R.S.M.; Chim, C.S.; Hanley, M.J.; Yang, H.; Venkatakrishnan, K. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Investigational New Drugs
2015 | Journal article
DOI: 10.1007/s10637-015-0230-x
EID:

2-s2.0-84939984782

Part of ISSN: 15730646 01676997
Contributors: Smith, D.C.; Kalebic, T.; Infante, J.R.; Siu, L.L.; Sullivan, D.; Vlahovic, G.; Kauh, J.S.; Gao, F.; Berger, A.J.; Tirrell, S. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: A population pharmacokinetic analysis

British Journal of Clinical Pharmacology
2015 | Journal article
DOI: 10.1111/bcp.12542
EID:

2-s2.0-84928317602

Part of ISSN: 13652125 03065251
Contributors: Gupta, N.; Zhao, Y.; Hui, A.-M.; Esseltine, D.-L.; Venkatakrishnan, K.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma

Future Oncology
2015 | Journal article
DOI: 10.2217/fon.15.9
EID:

2-s2.0-84926484321

Part of ISSN: 17448301 14796694
Contributors: Richardson, P.G.; Moreau, P.; Laubach, J.P.; Gupta, N.; Hui, A.-M.; Anderson, K.C.; San Miguel, J.F.; Kumar, S.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

Blood Cancer Journal
2014 | Journal article
DOI: 10.1038/bcj.2014.71
EID:

2-s2.0-84927752534

Part of ISSN: 20445385
Contributors: Assouline, S.E.; Chang, J.; Cheson, B.D.; Rifkin, R.; Hamburg, S.; Reyes, R.; Hui, A.-M.; Yu, J.; Gupta, N.; Di Bacco, A. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Blood
2014 | Journal article
DOI: 10.1182/blood-2014-01-548826
EID:

2-s2.0-84905962613

Part of ISSN: 15280020 00064971
Contributors: Richardson, P.G.; Baz, R.; Wang, M.; Jakubowiak, A.J.; Laubach, J.P.; Harvey, R.D.; Talpaz, M.; Berg, D.; Liu, G.; Yu, J. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Blood
2014 | Journal article
DOI: 10.1182/blood-2014-01-548941
EID:

2-s2.0-84905982938

Part of ISSN: 15280020 00064971
Contributors: Kumar, S.K.; Bensinger, W.I.; Zimmerman, T.M.; Reeder, C.B.; Berenson, J.R.; Berg, D.; Hui, A.-M.; Gupta, N.; Di Bacco, A.; Yu, J. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study

The Lancet Oncology
2014 | Journal article
DOI: 10.1016/S1470-2045(14)71125-8
EID:

2-s2.0-84925230724

Part of ISSN: 14745488 14702045
Contributors: Kumar, S.K.; Berdeja, J.G.; Niesvizky, R.; Lonial, S.; Laubach, J.P.; Hamadani, M.; Stewart, A.K.; Hari, P.; Roy, V.; Vescio, R. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology
2011 | Journal article
DOI: 10.1097/JTO.0b013e318220c93e
EID:

2-s2.0-80051801904

Part of ISSN: 15561380 15560864
Contributors: Tan, E.-H.; Goss, G.D.; Salgia, R.; Besse, B.; Gandara, D.R.; Hanna, N.H.; Yang, J.C.-H.; Thertulien, R.; Wertheim, M.; Mazieres, J. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

European Journal of Cancer
2011 | Journal article
DOI: 10.1016/j.ejca.2011.09.002
EID:

2-s2.0-82255160698

Part of ISSN: 09598049 18790852
Contributors: Tannir, N.M.; Wong, Y.-N.; Kollmannsberger, C.K.; Ernstoff, M.S.; Perry, D.J.; Appleman, L.J.; Posadas, E.M.; Cho, D.; Choueiri, T.K.; Coates, A. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

Journal of Clinical Oncology
2009 | Journal article
DOI: 10.1200/JCO.2008.21.7125
EID:

2-s2.0-70350464165

Part of ISSN: 0732183X
Contributors: Wong, C.-I.; Koh, T.-S.; Soo, R.; Hartono, S.; Thng, C.-H.; McKeegan, E.; Yong, W.-P.; Chen, C.-S.; Lee, S.-C.; Wong, J. et al.
Source: Self-asserted source
Neeraj Gupta via Scopus - Elsevier
Items per page:
Page 1 of 2

Peer review (1 review for 1 publication/grant)

Review activity for Clinical pharmacokinetics (1)
How many people are using ORCID?